SRTS Sensus Healthcare, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1494891 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-53.3%
TTM net income YoY-433.4%
TTM EPS YoY-438.9%
Revenue 3-yr CAGR-12.7%
Net income 3-yr CAGR—
Margins
Gross margin41.8%
Operating margin-74.0%
Net margin-96.5%
FCF margin-69.4%
EBITDA margin-71.9%
Returns
ROE-37.0%
ROA-32.4%
ROIC (approx.)-39.5%
Asset turnover0.34x
Leverage & solvency
Liabilities / assets12.6%
Debt / equity0.00x
Current ratio6.77x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.71x
Accruals ratio-9.5%
Payout ratio—
Capex / revenue1.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $27.48M | $41.81M | $24.41M | $44.53M | $27.04M |
| Cost of revenue | $15.62M | $17.38M | $10.35M | $14.90M | $10.05M |
| Gross profit | $11.87M | $24.43M | $14.06M | $29.63M | $16.99M |
| R&D expense | $7.78M | $4.22M | $3.68M | $3.46M | $3.44M |
| SG&A expense | $7.87M | $7.15M | $5.16M | $5.01M | $4.59M |
| Operating income | -$10.31M | $8.09M | -$382,000 | $14.83M | $4.12M |
| Interest expense | — | -$932,000 | -$992,000 | -$380,000 | $2,000 |
| Pretax income | -$9.62M | $9.02M | $652,000 | $27.99M | $4.12M |
| Income tax | -$1.91M | $2.38M | $167,000 | $3.75M | — |
| Net income | -$7.72M | $6.65M | $485,000 | $24.24M | $4.12M |
| EBITDA | -$9.91M | $8.29M | -$107,000 | $15.15M | $4.73M |
| EPS (basic) | -0.47 | 0.41 | 0.03 | 1.47 | 0.25 |
| EPS (diluted) | -0.47 | 0.41 | 0.03 | 1.46 | 0.25 |
| Weighted avg. shares (diluted) | 16.33M | 16.36M | 16.27M | 16.62M | 16.50M |
| Banking | |||||
| Net interest income | $683,000 | $932,000 | — | — | — |
| Balance sheet | |||||
| Cash & equivalents | $22.08M | $22.06M | $23.15M | $25.52M | $14.52M |
| Receivables | $6.04M | $19.73M | $10.64M | $17.30M | $12.13M |
| Inventory | $14.56M | $10.10M | $11.86M | $3.50M | $1.76M |
| Current assets | $45.89M | $56.74M | $49.53M | $53.24M | $31.25M |
| PP&E, net | $1.98M | $2.00M | $464,000 | $243,000 | $605,000 |
| Intangibles | — | — | — | $50,000 | $146,000 |
| Total assets | $53.04M | $62.16M | $53.71M | $56.73M | $32.24M |
| Current liabilities | $4.72M | $5.88M | $4.21M | $7.70M | $5.96M |
| Total liabilities | $4.94M | $6.34M | $4.87M | $8.67M | $6.22M |
| Shareholders' equity | $48.10M | $55.83M | $48.84M | $48.07M | $26.02M |
| Shares outstanding | 16.46M | 16.50M | 16.37M | 16.39M | 16.62M |
| Cash flow statement | |||||
| Operating cash flow | $528,000 | -$831,000 | -$2.15M | -$1.41M | -$286,000 |
| Capital expenditure | $196,000 | $276,000 | $229,000 | $159,000 | $128,000 |
| Free cash flow | $332,000 | -$1.11M | -$2.37M | -$1.57M | -$414,000 |
| Investing cash flow | -$196,000 | -$276,000 | -$187,000 | $14.84M | $129,000 |
| Financing cash flow | -$305,000 | $15,000 | -$40,000 | -$2.43M | -$231,000 |
| Depreciation & amortization | $400,000 | $200,000 | $275,000 | $315,000 | $613,000 |
| Stock-based compensation | $295,000 | $323,000 | $328,000 | $187,000 | $415,000 |
| Share buybacks | $300,000 | — | $27,000 | $3.00M | — |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.